CervoMed Inc. 10-Q

ITEM 5. OTHER INFORMATION   None.     ITEM 6. EXHIBITS   See attached Exhibit Index.   24     DIFFUSION PHARMACEUTICALS INC. QUARTERLY REPORT ON FORM 10-Q EXHIBIT INDEX   Exhibit No.   Description   Method of Filing 10.1   Employment Agreement, effective May 18, 2022, by and between the Company and Raven Jaeger, M.S.   Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed June 28, 2022 31.1   Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a)   Filed herewith 31.2   Certification of principal financial officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a)   Filed herewith 32.1   Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   Furnished herewith 32.2   Certification of principal financial officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   Furnished herewith 101   The following materials from Diffusion’s quarterly report on Form 10-Q for the quarter ended June 30, 2022 formatted in inline XBRL (Extensible Business Reporting Language): (i) the Unaudited Consolidated Balance Sheets, (ii) the Unaudited Consolidated Statements of Operations, (iii) the Unaudited Consolidated Statement of Changes in Stockholders’ Equity (Deficit), (iv) the Unaudited Consolidated Statements of Cash Flows, and (v) Notes to Unaudited Consolidated Financial Statements   Filed herewith 104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)       25     SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.   Date: August 11, 2022       DIFFUSION PHARMACEUTICALS INC.                           By: /s/ Robert J. Cobuzzi, Jr.       Robert J. Cobuzzi, Jr.       President and Chief Executive Officer       (Principal Executive Officer)                     By: /s/ William Hornung       William Hornung       Chief Financial Officer       (Principal Financial Officer and Principal Accounting Officer)